ARAY ACCURAY INC
Q4 2025 10-Q
Filed: Feb 17, 2026Period ending Dec 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR ACCURAY INC (ARAY) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 17, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ4 2025 10-Q
Risk Factors
- • New risk: Ongoing inflation and supply chain challenges driving higher material and logistics costs through fiscal 2026, pressuring gross margins and net income
- • Materially updated financial risk: Indebtedness $154.5M with $18M 2026 Notes due June 2026, including new warrants issued in June and Dec 2025 impacting dilution and liquidity
Quarterly Financial SummaryXBRL
Revenue
$102M
▼ -17.4% YoY▲ +8.8% QoQ
Net Income
-$14M
▼ -168.0% YoY▲ +36.5% QoQ
Gross Margin
24.0%
▼ -1625bp YoY▼ -426bp QoQ
Operating Margin
-11.3%
▼ -2252bp YoY▲ +73bp QoQ
Net Margin
-13.5%
▼ -2984bp YoY▲ +961bp QoQ
ROE
-25.8%
▼ -6808bp YoY
Total Assets
$448M
▼ -6.3% YoY
EPS (Diluted)
$-0.12
▼ -170.6% YoY▲ +33.3% QoQ
Operating Cash Flow
-$16M
▲ +9.5% YoY▼ -231.2% QoQ
Source: XBRL data from ACCURAY INC Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ACCURAY INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.